

ASSOC.PROF. PD. MAG. DR. WOLFGANG WADSAK

* 18. July 1972 (in Vienna, Austria)

Head of Medicinal Radiochemistry and Biomarker Development Unit
Department of Biomedical Imaging and Image-guided Therapy
Division of Nuclear Medicine

Medical University of Vienna
Spitalgasse 23
A-1090 Vienna, Austria

T: +43-1-40400-55330
@: wolfgang.wadsak@meduniwien.ac.at
web: www.radiopharmaceutical-sciences.net



PERSONAL INFORMATION

- ◇ 22.02.2000 Marriage with Mag.iur. Eva Triebel
- ◇ 09.08.2001 Birth of son, Thomas
- ◇ 17.03.2003 Birth of son, Alexander
- ◇ 26.10.2005 Birth of son, Clemens
- ◇ 29.06.2007 Birth of daughter, Meghann Marie

RESEARCH FOCUS

- ◇ Development and preclinical testing of PET radioligands specific for the adenosine A3 receptor (A3R)
- ◇ Development and preclinical testing of PET radioligands specific for the norepinephrine transporter (NET)
- ◇ Development and preclinical testing of PET radioligands specific for the melanin concentrating hormone receptor (MCHR1)
- ◇ Evaluation and optimization of microfluidic syntheses of PET tracers and their comparison with conventional (vessel-based) radiosyntheses
- ◇ ¹⁸F-fluoroethylations as rapid tool for the translation of ¹¹C-methylated radiotracers into longer-lived analogues

SCIENTIFIC EDUCATION

- 2011** 4-month scientific visit at ETH Zurich, Switzerland
- 2009** Postdoctoral thesis („Habilitation“; Medicinal Radiochemistry), Medical University of Vienna
- 2003-2004** Post-graduate diploma in Radiopharmaceutical Chemistry, ETH Zurich/ Universities of Frankfurt and Leipzig
- 2000-2004** PhD study (Radiochemistry), University of Vienna
- 1991-1999** Master study in Chemistry, University of Vienna

OCCUPATION

- Since 2012** Associate Professor for Medicinal Radiochemistry, Head of Medicinal Radiochemistry and Biomarker Development Unit, Medical University of Vienna
- 2010-2012** Assistant Professor, Radiochemistry and Biomarker Development Unit, Medical University of Vienna
- 2009-2010** Senior Post-Doc, Medical University of Vienna
- Since 2009** Lector in “Physiology and Pathology for Functional Imaging 1” at the University of applied sciences Wiener Neustadt (Master course “MedTech”)

- Since 2005** Radiation protection agent – Radiochemistry Labs, Radiopharmacy, Psychiatry and Preclinical Imaging Lab (PIL)
- Since 2005** Lector for “Medicinal Radiochemistry 1+2” at the University of Vienna
- Since 2004** Trainer and consultant for Bayer AG (*formerly Schering AG*), Vienna - ⁹⁰Y-Zevalin for radioimmunotherapy
- Since 2003** Lector in “Radiopharmacy” at the academy for radiology technologists in Vienna (now: University of Applied Sciences, Vienna)
- Since 2001** Production Manager for PET Radiopharmaceuticals, Department of Nuclear Medicine, Medical University of Vienna
- 2001-2009** University assistant, Medical University of Vienna
- 1999-2001** PhD student and research fellow, Department of Nuclear Medicine, Medical University of Vienna

AWARDS

- 2006 & 2008** THP Award for Basic Sciences in Nuclear Medicine
- 2004** Winner of the Scholarship „Dr. Pfeiffer-Stipendium“, Austrian Society for Nuclear Medicine and Molecular Imaging (OGN)
- 1997 & 1998** Scholarship for extraordinary achievements, University of Vienna

MEMBERSHIPS

- Since 2009** Full member in the European Association of Nuclear Medicine (EANM)
- Since 2005** Full member in the Society of Radiopharmaceutical Sciences (SRS)
- Since 2003** Member in the Austrian Society for Nuclear Medicine and Molecular Imaging (OGN)

REVIEWER & EDITORIAL BOARDS

- Since 2014** Editorial Board Member in *International Journal of Radiology*
- Since 2014** Editorial Board Member in *Journal of Molecular Biomarkers & Diagnosis*
- Since 2013** Reviewer for *Molecules*
- Since 2012** Editorial Board Member in *Scientifica*
- Since 2009** Reviewer for *Nuclear Medicine and Biology* and *Applied Radiation and Isotopes*
- Since 2008** Editorial Board Member in *The Open Nuclear Medicine Journal*
- Since 2008** Reviewer for *European Journal of Nuclear Medicine and Molecular Imaging*
- Since 2007** Reviewer for *European Journal of Radiology*

GRANTS

- 2002-2007** Project manager for the project #8263 (Jubilaeumsfonds of the Austrian Federal Bank)
- Since 2007** Project manager of 9 industry sponsored research projects
- Since 2003** Co-investigator in multiple Austrian Science Fund, Austrian Federal Bank or industry sponsored projects (Total sum: € 3,589.515,-)

INTERNATIONAL COOPERATIONS

- ✧ **ETH Zurich**
Center for Radiopharmaceutical Sciences; Zurich, Switzerland
- ✧ **University of Tuebingen**
Division for preclinical imaging and radiopharmacy; Tuebingen, Germany
- ✧ **National Inst. of Radiological Sciences Chiba**
Department of Molecular Probes, Molecular Imaging Center; Chiba, Japan

LECTURES & TEACHING

- Since 2009** Lector in “Physiology and Pathology for Functional Imaging 1” at the University of applied sciences Wiener Neustadt (Master course “MedTech”)
- Since 2008** Lector in “Innovative Technologies (NeuroImaging)” at the University of applied sciences, Wiener Neustadt
- Since 2006** Lector for specific scientific module 1 (SSM1) at the Medical University of Vienna
- Since 2005** Lector for “Medicinal Radiochemistry” and “Medicinal Radiochemistry 2 – Tracer for NeuroImaging” at the University of Vienna
- Since 2003** Lector in “Radiopharmacy” at the academy for radiology technologists in Vienna (now: University of Applied Sciences, Vienna)

TOP 10 PUBLICATIONS (in order of appearance)

- [1] **Wadsak W**, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettlinger DE, Dudczak R, Kletter K, Karanikas G. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. *Eur J Nucl Med Mol Imaging* 2006; 33: 669-672.
- [2] **Wadsak W**, Mien LK, Ettlinger DE, Eidherr H, Haeusler D, Sindelar KM, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. [18F]Fluoroethylations: Different strategies for the rapid translation of [11C]methylated Radiotracers. *Nucl Med Biol* 2007; 34: 1019-1028.
- [3] Lanzenberger RR, Mitterhauser M, Spindelegger C, **Wadsak W**, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. *Biol Psych* 2007; 61: 1081-1089.
- [4] **Wadsak W**, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar KM, Lanzenberger RR, Spreitzer H, Viernstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. Preparation and first evaluation of [18F]FE@SUPPY: a new PET-Tracer for the Adenosine A3 Receptor. *Nucl Med Biol* 2008; 35:61-66.
- [5] **Wadsak W** and Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. *Eur J Rad* 2010; 73:461-469.
- [6] Selivanova SV, Mu L, Ungersboeck J, Stellfeld T, Ametamey SM, Schibli R, **Wadsak W**. Single-step radiofluorination of peptides using continuous flow microreactor. *Org Biomol Chem* 2012; 10: 3871-3874.
- [7] Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Shanab K, Lanzenberger R, Spreitzer H, Viernstein H, Mitterhauser M, **Wadsak W**. [18F]FE@SNAP - a new PET tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1): microfluidic and vessel-based approaches. *Bioorg Med Chem* 2012; 20:5936-5940.
- [8] Hahn A, **Wadsak W**, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors. *Proc Natl Acad Sci* 2012; 109:2619-24.
- [9] Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, **Wadsak W**, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. *Mol Psych* 2013; 18:93-100.
- [10] Rami-Mark C, Zhang MR, Mitterhauser M, Lanzenberger R, **Wadsak W**. [18F]FMENER-D2: Reliable fully-automated synthesis for clinical visualization of the norepinephrine transporter. *Nucl Med Biol* 2013; 40:1049-54.

PUBLICATION LIST (complete -2014)

First & Senior Author

- [1] Wadsak W, Hrneck E, Irlweck K. Formation of americium(III) complexes with aqueous silicic acid. *Radiochimica Acta* 2000; 88: 61-64.
- [2] Wadsak W and Mitterhauser M. Synthesis of [18F]FETO, a novel potential 11- β hydroxylase inhibitor. *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; 46: 379-388.

- [3] Wadsak W, Mitterhauser M, Mien LK, Tögel S, Keppler B, Dudczak R, Kletter K. Radiosynthesis of 3-(2'-[¹⁸F]Fluoro)-flumazenil ([¹⁸F]FFMZ). *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; 46: 1229-1240.
- [4] Wadsak W, Wirl-Sagadin B, Mitterhauser M, Mien LK, Ettliger DE, Dudczak R, Kletter K. N.c.a. nucleophilic radiofluorination on substituted benzaldehydes for the preparation of [¹⁸F]fluorinated aromatic amino acids. *Applied Radiation and Isotopes* 2006; 64: 355-359.
- [5] Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien LK, Ettliger DE, Dudczak R, Kletter K, Karanikas G. [¹⁸F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; 33: 669-672.
- [6] Mitterhauser M and Wadsak W. [¹⁸F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity. (Letter to the editor) *Journal of Clinical Endocrinology and Metabolism* 2006.
- [7] Mitterhauser M and Wadsak W. Evaluation of novel tropane analogues. (Letter to the editor) *Nuclear Medicine and Biology* 2007; 34: 591-592.
- [8] Wadsak W, Mien LK, Ettliger DE, Feitscher S, Lanzenberger R, Marton J, Dudczak R, Kletter K, Mitterhauser M. Preparation and Radiosynthesis of [¹⁸F]FE@CFN (2-[¹⁸F]fluoroethyl 4-[N-(1-oxopropyl)-N-phenylamino]-1-(2-phenylethyl)-4-piperidinecarboxylate), a Potential μ -Opioid Receptor Imaging Agent. *Radiochimica Acta* 2007; 95: 33-38.
- [9] Wadsak W, Mien LK, Ettliger DE, Lanzenberger R, Haeusler D, Dudczak R, Kletter K, Mitterhauser M. Simple and fully automated preparation of [carbonyl-¹¹C]WAY-100635. *Radiochimica Acta* 2007; 95: 417-422.
- [10] Wadsak W, Mien LK, Ettliger DE, Eidherr H, Haeusler D, Sindelar KM, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. [¹⁸F]Fluoroethylations: Different strategies for the rapid translation of [¹¹C]methylated Radiotracers. *Nuclear Medicine and Biology* 2007; 34: 1019-1028.
- [11] Wadsak W, Mien LK, Shanab K, Ettliger DE, Haeusler D, Sindelar KM, Lanzenberger RR, Spreitzer H, Viernstein H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M. Preparation and first evaluation of [¹⁸F]FE@SUPPY: a new PET-Tracer for the Adenosine A₃ Receptor. *Nuclear Medicine and Biology* 2008; 35:61-66.
- [12] Wadsak W, Mien LK, Shanab K, Weber K, Schmidt B, Sindelar KM, Ettliger DE, Haeusler D, Spreitzer H, Keppler BK, Viernstein H, Dudczak R, Kletter K, Mitterhauser M. Radiosynthesis of the adenosine A₃ receptor ligand 5-(2-[¹⁸F]fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY). *Radiochimica Acta* 2008; 96:119-124.
- [13] Haeusler D, Mien LK, Nics L, Ungersboeck J, Philippe C, Lanzenberger RR, Kletter K, Dudczak R, Mitterhauser M, Wadsak W. Simple and rapid preparation of [¹¹C]DASB with high quality and reliability for routine applications. *Applied Radiation and Isotopes* 2009; 67: 1654-1660.
- [14] Haeusler D, Mitterhauser M, Mien LK, Shanab K, Lanzenberger RR, Schirmer E, Ungersboeck J, Nics L, Spreitzer H, Viernstein H, Dudczak R, Kletter K, Wadsak W. Radiosynthesis of a novel potential adenosine A₃ receptor ligand, 5-ethyl 2,4-diethyl-3-((2-[¹⁸F]fluoroethyl)sulfanylcarbonyl)-6-phenylpyridine-5-carboxylate ([¹⁸F]FE@SUPPY:2). *Radiochimica Acta* 2009; 97: 753-758.
- [15] Mitterhauser M, Haeusler D, Mien LK, Ungersboeck J, Nics L, Lanzenberger R, Sindelar K, Viernstein H, Dudczak R, Kletter K, Spreitzer H, Wadsak W. Automatisations and first evaluation of [¹⁸F]FE@SUPPY:2, an alternative PET-Tracer for the Adenosine A₃ Receptor: A Comparison with [¹⁸F]FE@SUPPY. *The Open Nuclear Medicine Journal* 2009; 1: 15-23.
- [16] Wadsak W and Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. *European Journal of Radiology* 2010; 73:461-469.
- [17] Ungersboeck J, Philippe C, Mien LK, Haeusler D, Shanab K, Lanzenberger R, Spreitzer H, Keppler BK, Dudczak R, Kletter K, Mitterhauser M, Wadsak W. Microchemical Preparation of [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 – comparison with conventional radiosyntheses. *Nuclear Medicine and Biology* 2011; 38: 427-434.
- [18] Philippe C, Haeusler D, Mitterhauser M, Ungersboeck J, Viernstein H, Dudczak R, Wadsak W. Optimization of the radiosynthesis of the Alzheimer tracer 2-(4-N-[¹¹C]methylaminophenyl)-6-hydroxybenzothiazole ([¹¹C]PIB). *Applied Radiation and Isotopes* 2011; 69: 1212-1217.
- [19] Selivanova SV, Mu L, Ungersboeck J, Stellfeld T, Ametamey SM, Schibli R, Wadsak W. Single-step radiofluorination of peptides using continuous flow microreactor. *Organic and Biomolecular Chemistry* 2012; 10: 3871-3874.

- [20] Ungersboeck J, Richter S, Collier TL, Mitterhauser M, Karanikas G, Lanzenberger R, Dudczak R, Wadsak W. Radiolabelling of [¹⁸F]altanserin – a microfluidic approach. *Nuclear Medicine and Biology* 2012; 39:1087-1092.
- [21] Philippe C, Schirmer E, Mitterhauser M, Shanab K, Spreitzer H, Viernstein H, Wadsak W. Radiosynthesis of [¹¹C]SNAP-7941 – the first PET-Tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1). *Applied Radiation and Isotopes* 2012; 70:2287–2294.
- [22] Ungersboeck J, Philippe C, Haeusler D, Mitterhauser M, Lanzenberger R, Dudczak R, Wadsak W. Optimization of [¹¹C]DASB-synthesis: microfluidic and vessel-based methods. *Applied Radiation and Isotopes* 2012; 70:2615–2620.
- [23] Philippe C, Ungersboeck J, Schirmer E, Zdravkovic M, Shanab K, Lanzenberger R, Spreitzer H, Viernstein H, Mitterhauser M, Wadsak W. [¹⁸F]FE@SNAP - a new PET tracer for the Melanin Concentrating Hormone Receptor 1 (MCHR1): microfluidic and vessel-based approaches. *Bioorganic and Medicinal Chemistry* 2012; 20:5936-5940.
- [24] Mark C, Bornatowicz B, Nics L, Haeusler D, Hendl M, Berger M, Lanzenberger R, Karanikas G, Spreitzer H, Mitterhauser M, Wadsak W. Development and evaluation of a novel PET tracer for the norepinephrine transporter: [¹¹C]Me@APPI. *Nuclear Medicine and Biology* 2013; 40:295-303.
- [25] Rami-Mark C, Ungersboeck J, Haeusler D, Nics L, Philippe C, Mitterhauser M, Willeit M, Lanzenberger R, Karanikas G, Wadsak W. Reliable set-up for in-loop ¹¹C-carboxylations using Grignard reactions for the preparation of [carbonyl-¹¹C]WAY-100635 and [¹¹C]-(+)-PHNO. *Applied Radiation and Isotopes* 2013; 82:75-80.
- [26] Rami-Mark C, Zhang MR, Mitterhauser M, Lanzenberger R, Wadsak W. [¹⁸F]FMeNER-D2: Reliable fully-automated synthesis for clinical visualization of the norepinephrine transporter. *Nuclear Medicine and Biology* 2013; 40:1049-1054.
- [27] Rami-Mark C, Bornatowicz B, Fink C, Otter P, Ungersboeck J, Vranka C, Haeusler D, Nics L, Spreitzer H, Hacker M, Mitterhauser M, Wadsak W. Synthesis, radiosynthesis and first in-vitro evaluation of novel PET-tracers for the dopamine transporter: [¹¹C]IPCIT and [¹⁸F]FE@IPCIT. *Bioorganic and Medicinal Chemistry* 2013; 21:7562-7569.
- [28] Mitterhauser M and Wadsak W. Imaging Biomarkers or Biomarker Imaging? *Pharmaceuticals* 2014; 7:765-778.

Co-Author

- [29] Langer O, Mitterhauser M, Brunner M, Zeitlinger M, Wadsak W, Mayer BX, Kletter K, Müller M. Synthesis of fluorine-18-labeled Ciprofloxacin for Pet studies in humans. *Nuclear Medicine and Biology* 2003; 30:285-291.
- [30] Langer O, Mitterhauser M, Wadsak W, Brunner M, Müller U, Kletter K, Müller M. A general method for the fluorine-18 labelling of fluoroquinolone antibiotics. *Journal of Labelled Compounds and Radiopharmaceuticals* 2003; 46: 715-727.
- [31] Becherer A, Karanikas G, Szabó M, Georg G, Asenbaum S, Marosi C, Henk C, Wunderbaldinger P, Czech T, Wadsak W, Kletter K. Brain tumour imaging with PET: a comparison between [¹⁸F]fluorodopa and [¹¹C]methionine. *European Journal of Nuclear Medicine and Molecular Imaging* 2003; 30: 1561-1566.
- [32] Mitterhauser M, Wadsak W, Langer O, Schmaljohann J, Zetting G, Dudczak R, Viernstein H, Kletter K. Comparison of three different purification methods for the routine preparation of [¹¹C] Metomidate. *Applied Radiation and Isotopes* 2003; 59: 125-128.
- [33] Mitterhauser M, Wadsak W, Wabnegger L, Sieghart W, Viernstein H, Kletter K, Dudczak R. In vivo and in vitro evaluation of [¹⁸F]FETO on the adrenocortical and GABAergic System in rats. *European Journal of Nuclear Medicine and Molecular Imaging* 2003; 30:1398-1401.
- [34] Mitterhauser M, Wadsak W, Mien LK, Eidherr H, Roka S, Zetting G, Angelberger P, Viernstein H, Kletter K, Dudczak R. The labelling of Nanocoll® with [¹¹¹In] for dual-isotope scanning. *Applied Radiation and Isotopes* 2003; 59: 337-342.
- [35] Mitterhauser M, Wadsak W, Eidherr H, Krcal A, Kletter K, Dudczak R, Viernstein H, Pirich C. Labelling of EDTMP (Multibone) with [¹¹¹In], [^{99m}Tc] and [¹⁸⁸Re] using different carriers for “cross complexation”. *Applied Radiation and Isotopes* 2004; 60: 653-658.

- [36] Mitterhauser M, Wadsak W, Wabnegger L, Mien LK, Tögel S, Langer O, Sieghart W, Viernstein H, Kletter K, Dudczak R. In vivo and in vitro evaluation of [18F]fluoroflumazenil ([18F]FFMZ) on rats. *Nuclear Medicine and Biology* 2004; 31: 291-295.
- [37] Füger B, Mitterhauser M, Wadsak W, Ofluoglu S, Traub T, Karanikas G, Dudczak R, Pirich C. Bone lesion detection with carrier added Tc-99m EDTMP in comparison to Tc-99m DPD. *Nuclear Medicine Communications* 2004; 25: 361-365.
- [38] Mitterhauser M, Tögel S, Wadsak W, Mien LK, Eidherr H, Wiesner K, Viernstein H, Kletter K, Dudczak R. Binding studies of [18F]-fluoride and Polyphosphonates radiolabelled with [111In], [99mTc], [153Sm] and [188Re] on bone compartments: A new model for the pre vivo-evaluation of bone seekers? *Bone* 2004; 34: 835-844.
- [39] Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Bartosch E, Eidherr H, Viernstein H, Kletter K. New aspects on the preparation of [11C]Acetate – a simple and fast approach via distillation. *Applied Radiation and Isotopes* 2004, 61: 1147-1150.
- [40] Zetting G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K. Positron emission tomography imaging of adrenal masses: F-18 Fluorodesoxyglucose and the 11-beta hydroxylase-tracer C-11-metomidate. *European Journal of Nuclear Medicine and Molecular Imaging* 2004; 31: 1224-1230.
- [41] Brunner M, Langer O, Dobrozemsky G, Müller U, Zeitlinger M, Mitterhauser M, Wadsak W, Dudczak R, Kletter K, Müller M. [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of Ciprofloxacin in humans. *Antimicrobial Agents and Chemotherapy* 2004;48: 3850-3857.
- [42] Mitterhauser M, Wadsak W, Mien LK, Hoeppling A, Viernstein H, Dudczak R, Kletter K. Synthesis and Biodistribution of [18F]FE@CIT, a new potential tracer for the Dopamine Transporter. *Synapse* 2005, 55: 73-79.
- [43] Langer O, Brunner M, Zeitlinger M, Ziegler S, Müller U, Dobrozemsky G, Lackner E, Joukhader C, Mitterhauser M, Wadsak W, Minar E, Dudczak R, Kletter K, Müller M. In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. *European Journal of Nuclear Medicine and Molecular Imaging* 2005; 32: 143-150.
- [44] Mitterhauser M, Wadsak W, Krcal A, Schmaljohann J, Eidherr H, Viernstein H, Kletter K. New aspects on the preparation of [11C]Methionine – a simple and fast online approach without preparative HPLC. *Applied Radiation and Isotopes* 2005; 62: 441-445.
- [45] Brunner M, Langer O, Sunder-Plassmann R, Dobrozemsky G, Müller U, Wadsak W, Krcal A, Karch R, Mannhalter C, Dudczak R, Kletter K, Steiner I, Baumgartner C, Müller M. Influence of functional haplotypes in the drug transporter gene ABCB1 on CNS drug distribution in humans. *Clinical Pharmacology and Therapeutics* 2005; 78: 182-190.
- [46] Mitterhauser M, Toegel S, Wadsak W, Mien KL, Eidherr H, Kletter K, Viernstein H, Kluger R, Engel A, Dudczak R. Binding studies of [18F]-fluoride and polyphosphonates radiolabelled with [99mTc], [111In], [153Sm] and [188Re] on bone compartments: Verification of the pre vivo model? *Bone* 2005; 37: 404-412.
- [47] Khorsand A, Graf S, Eidherr H, Wadsak W, Kletter K, Sochor H, Schuster E, Porenta G. Gated cardiac 13NH3 PET for assessment of left ventricular volumes, mass, and ejection fraction: Comparison with electrocardiography-gated 18F-FDG PET. *The Journal of Nuclear Medicine* 2005; 46: 2009-2013.
- [48] Toegel S, Hoffmann O, Wadsak W, Ettliger DE, MienLK, Wiesner K, Nguemo J, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Uptake of bone seekers is solely associated with mineralisation! A study with [99mTc]-MDP, [153Sm]-EDTMP and [18F]-fluoride on osteoblasts. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; 33: 491-494.
- [49] Ettliger DE, Wadsak W, MienLK, Machek M, Wabnegger L, Rendl G, Karanikas G, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. [18F]FETO: metabolic considerations. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; 33: 928-931.
- [50] Ettliger DE, Mitterhauser M, Wadsak W, Ostermann E, Farkouh A, Schueller J, Czejka M. In vivo disposition of Irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody Cetuximab. *Anticancer Research* 2006; 26: 1337-1342.
- [51] Mitterhauser M, Dobrozemsky G, Zettinig G, Wadsak W, Vierhapper H, Dudczak R, Kletter K. Imaging of adrenocortical metastases with [11C]metomidate. *European Journal of Nuclear Medicine and Molecular Imaging* 2006; 33: 974.

- [52] Toegel S, Mien LK, Wadsak W, Eidherr H, Viernstein H, Kluger R, Ettliger D, Kletter K, Dudczak R, Mitterhauser M. In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory". *Nuclear Medicine and Biology* 2006; 33: 95-99.
- [53] Lanzenberger RR, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. Reduced serotonin-1A receptor binding in social anxiety disorder. *Biological Psychiatry* 2007; 61: 1081-1089.
- [54] Mitterhauser M, Toegel S, Wadsak W, Lanzenberger R, Mien LK, Kuntner C, Wanek T, Eidherr H, Ettliger DE, Viernstein H, Kluger R, Dudczak R, Kletter K. Pre-, Ex- and In-vivo Evaluation of [68Ga]-EDTMP. *Nuclear Medicine and Biology* 2007; 34: 391-397.
- [55] Fischer MB, Ruger B, Vaculik C, Becherer A, Wadsak W, Yanagida G, Losert UM, Chen J, Carroll MC, Eibl MM. The presence of MOMA-2(+) macrophages in the outer B cell zone and protection of the splenic micro-architecture from LPS-induced destruction depend on secreted IgM. *European Journal of Immunology* 2007; 37: 2825-2833.
- [56] Toegel S, Wadsak W, Mien LK, Viernstein H, Kluger R, Eidherr H, Haeusler D, Kletter K, Dudczak R, Mitterhauser M. Preparation and pre-vivo evaluation of no-carrier-added, carrier-added and cross-complexed [⁶⁸Ga]-EDTMP formulations. *European Journal of Pharmaceutics and Biopharmaceutics*; 2008; 68: 406-412.
- [57] Shanab K, Wadsak W, Mien LK, Mitterhauser M, Holzer W, Polster V, Spreitzer H. Synthesis of in vivo metabolites of the new Adenosine A3 receptor PET-radiotracer [18F]FE@SUPPY. *Heterocycles* 2008; 75: 339-356.
- [58] Ettliger DE, Haeusler D, Wadsak W, Girschele F, Sindelar KM, Mien LK, Ungersboeck J, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Metabolism and Autoradiographic Evaluation of [18F]FE@CIT: A comparison with [123I]β-CIT and [123I]FP-CIT. *Nuclear Medicine and Biology* 2008; 35: 475-479.
- [59] Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R. Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET. *NeuroImage* 2008; 41:204-211.
- [60] Bankstahl JP, Kuntner C, Abraham A, Karch R, Stanek J, Wanek T, Zsebedics M, Wadsak W, Kletter K, Kvaternik H, Müller M, Löscher W, Langer O. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-¹¹C-verapamil and PET. *Journal of Nuclear Medicine* 2008; 49: 1328-1335.
- [61] Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien LK, Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R. The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-¹¹C]WAY-100635. *European Journal of Nuclear Medicine and Molecular Imaging* 2008; 35:2159–2168.
- [62] Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M, Moser U, Holik A, Kletter K, Kasper S. Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders. *Molecular Psychiatry* 2009; 14: 1040-50.
- [63] Witte V, Flöel A, Stein P, Savli M, Mien LK, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, Lanzenberger R. Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects. *Human Brain Mapping* 2009; 30:2558-2570.
- [64] Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien LK, Kletter K, Mitterhauser M, Kasper S, Lanzenberger R. Lateralization of serotonin-1A receptor distribution in language areas associated with sex. *NeuroImage* 2009; 45(2):598-605.
- [65] Philippe C, Mien LK, Salar-Behzadi S, Knaeusl B, Wadsak W, Dudczak R, Kletter K, Viernstein H, Mitterhauser M. "Label and go" - a fast and easy radiolabelling method for pellets. *Applied Radiation and Isotopes* 2010; 68:399-403.
- [66] Haeusler D, Nics L, Mien LK, Ungersboeck J, Lanzenberger RR, Shanab K, Sindelar KM, Viernstein H, Wagner KH, Dudczak R, Kletter K, Wadsak W, Mitterhauser M. [¹⁸F]FE@SUPPY and [¹⁸F]FE@SUPPY:2 - Metabolic considerations. *Nuclear Medicine and Biology* 2010; 37:421-426.
- [67] Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien LK, Bieglmayer C, Kletter K, Kasper S, Lanzenberger R. Hypothalamic serotonin-1A receptor binding measured by PET predicts the

- plasma level of dehydroepiandrosterone sulfate in healthy women. *Neuroscience Letters* 2010; 476:161-165.
- [68] Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien LK, Fink M, Moser U, Savli M, Kranz C, Hahn A, Kletter K, Kasper S. Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions. *International Journal of Neuropsychopharmacology* 2010; 13:1129-1143.
- [69] Assem-Hilger E, Lanzenberger R, Savli M, Wadsak W, Mitterhauser M, Mien LK, Stoegmann E, Baumgartner C, Kletter K, Asenbaum S. Central 5-HT_{1A} receptor binding in Temporal Lobe Epilepsy: a [¹¹C]WAY-100635 PET study. *Epilepsy and Behaviour* 2010; 19:467-473.
- [70] Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien LK, Mitterhauser M, Kasper S. Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. *Journal of Neuroscience* 2010; 30:14482-14489.
- [71] Nics L, Haeusler D, Wadsak W, Wagner KH, Dudczak R, Kletter K, Mitterhauser M. The stability of methyl-, ethyl-, and fluoroethyl-esters against Carboxylesterases in-vitro: there is no difference. *Nuclear Medicine and Biology* 2011; 38:13-17.
- [72] Lanzenberger R, Mitterhauser M, Kranz GS, Spindelegger C, Wadsak W, Stein P, Moser U, Kletter K, Kasper S. Progesterone level predicts serotonin-1A receptor binding in the male human brain. *Neuroendocrinology* 2011; 94: 84-88.
- [73] Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien LK, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R. Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain. *World J Biol Psychiatry* 2012; 13:413-22.
- [74] Bauer M, Zeitlinger M, Karch R, Matzneller P, Stanek J, Jäger W, Böhmendorfer M, Wadsak W, Mitterhauser M, Bankstahl JP, Löscher W, Koepf M, Kuntner C, Müller M, Langer O. Pgp-Mediated Interaction Between (R)-[¹¹C]Verapamil and Tariquidar at the Human Blood-Brain Barrier: A Comparison With Rat Data. *Clinical Pharmacology and Therapeutics* 2012; 91:227-33.
- [75] Hahn A, Wadsak W, Windischberger C, Baldinger P, Höflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R. Differential modulation of the default mode network via serotonin-1A receptors. *Proceedings of the National Academy of Sciences of the USA* 2012; 109:2619-24.
- [76] Baldinger P, Hahn A, Friedl M, Kranz GS, Ungersboeck J, Höflich A, Mitterhauser M, Rujescu D, Wadsak W, Lanzenberger R, Kasper S. Influence of the HTR_{1A} polymorphism rs878567 on the serotonin 1a binding potential in vivo. *Journal für Neurologie, Neurochirurgie und Psychiatrie* 2012;13:36-38.
- [77] Hahn A, Nics L, Baldinger P, Ungersboeck J, Schuetz M, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, , Karanikas G, Kasper S, Lanzenberger R. Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-¹¹C]WAY-100635 independent of arterial sampling. *Neuroimage* 2012; 62:199–206.
- [78] Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET. *Molecular Psychiatry* 2013; 18:93-100.
- [79] Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R. Impact of electroconvulsive therapy on 5-HT_{1A} receptor binding in major depression. *Molecular Psychiatry* 2013; 18:1. (Image)
- [80] Savli M, Bauer A, Mitterhauser M, Ding YS, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani SA, Rattay F, Wadsak W, Kasper S, Lanzenberger R. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. *Neuroimage* 2012 63:447-459.
- [81] Lanzenberger R, Kranz GS, Haeusler D, Akimova E, Savli M, Hahn A, Wadsak W, Spindelegger C, Philippe C, Fink M, Mitterhauser M, Kasper S. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas. *Neuroimage* 2012; 63:874-881.
- [82] Kraus C, Hahn A, Savli M, Kranz GS, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R.

- Serotonin-1A receptor binding is positively associated gray matter volume – A multimodal neuroimaging study combining PET and structural MRI. *Neuroimage* 2012; 63:1091-1098.
- [83] Nics L, Hahn A, Zeilinger M, Vraka C, Ungersboeck J, Haeusler D, Hartmann S, Wagner KH, Dudczak R, Lanzenberger R, Wadsak W, Mitterhauser M. Quantification of the serotonin-1A receptor radioligand [carbonyl-¹¹C]WAY-100635 and its radio-metabolites in human plasma: An improved HPLC-assay allowing two parallel patients. *Applied Radiation and Isotopes* 2012; 70:2730-2736.
- [84] Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W, Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R. Application of image-derived and venous input functions in major depression using [carbonyl-¹¹C]WAY-100635. *Nuclear Medicine and Biology* 2013; 40:371-377.
- [85] Mayerhoefer ME, Ba-Ssalamah A, Weber M, Mitterhauser M, Eidherr H, Wadsak W, Trattng S, Herneth A, Karanikas G. Gadoxetate-enhanced versus Diffusion-weighted MRI for Fused ⁶⁸Ga-DOTANOC PET/MRI in Patients with Neuroendocrine Tumors of the Upper Abdomen. *European Radiology* 2013; 23:1978-85.
- [86] Bauer M, Karch R, Zeitlinger M, Stanek J, Philippe C, Wadsak W, Mitterhauser M, Jäger W, Haslacher H, Müller M, Langer O. Interaction of ¹¹C-tariquidar and ¹¹C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. *Journal of Nuclear Medicine* 2013; 54:1181-1187.
- [87] Philippe C, Nics L, Zeilinger M, Kuntner C, Wanek T, Mairinger S, Shanab K, Spreitzer H, Viernstein H, Wadsak W, Mitterhauser M. Preclinical in vitro & in vivo evaluation of [¹¹C]SNAP-7941 - the first PET tracer for the melanin concentrating hormone receptor 1. *Nuclear Medicine and Biology* 2013; 40: 919-925.
- [88] Toth DF, Raderer M, Wadsak W, Karanikas G. Beta-2 Microglobulin as a Diagnostic Parameter in Non-Hodgkin Lymphoma: A Comparative Study with FDG-PET. *Anticancer Research* 2013; 33:3341-3345.
- [89] Philippe C, Nics L, Zeilinger M, Schirmer E, Spreitzer H, Karanikas G, Lanzenberger R, Viernstein H, Wadsak W, Mitterhauser M. Preparation and first preclinical evaluation of [¹⁸F]FE@SNAP: a new PET tracer for the melanin concentrating hormone receptor 1 (MCHR1). *Scientia Pharmaceutica* 2013; 81:625-639.
- [90] Baldinger P, Hahn A, Mitterhauser M, Kranz G, Friedl M, Wadsak W, Kraus C, Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R. Impact of COMT genotype on serotonin-1A receptor binding investigated with PET. *Brain Structure and Function* 2013, Aug 9. [Epub ahead of print].
- [91] Schirmer E, Shanab K, Datterl B, Neudorfer C, Mitterhauser M, Wadsak W, Philippe C, Spreitzer H. Syntheses of precursors and reference compounds of the MCHR1 PET tracers [¹¹C]SNAP-7941 and [¹⁸F]FE@SNAP. *Molecules* 2013; *Molecules* 2013; 18:12119-12143.
- [92] Baldinger P, Kranz GS, Häusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. *NeuroImage* 2014; 88:252-262.
- [93] Kranz GS, Hahn A, Baldinger P, Häusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Höflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R. Cerebral serotonin transporter asymmetry in males and male-to-female transsexuals: a PET study with [¹¹C]DASB. *Brain Structure and Function* 2014; 219:171-183.
- [94] Hahn A, Haeusler D, Kraus C, Höflich A, Kranz GS, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R. Attenuated serotonin transporter association between midbrain dorsal raphe and ventral striatum in major depression. *Human Brain Mapping* 2014; 35:3857-3866.
- [95] Shanab K, Neudorfer C, Holzer W, Mitterhauser M, Wadsak W, Spreitzer H. A one-step microwave assisted synthetic method for an O/S-chemoselective route to derivatives of the first adenosine A3 PET radiotracer. *Molecules* 2014; 19:4076-4082.
- [96] Philippe C, Haeusler D, Fuchshuber F, Spreitzer H, Viernstein H, Hacker M, Wadsak W, Mitterhauser M. Comparative in-vitro autoradiographic investigation of the melanin concentrating hormone receptor 1 in the central nervous system. *European Journal of Pharmacology* 2014; 735C:177-183.

- [97] Stein P, Baldinger P, Kaufmann U, Rami-Mark C, Hahn A, Höflich A, Kranz GS, Savli M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R. Relation of progesterone and DHEAS serum levels to 5-HT_{1A} receptor binding potential in pre- and postmenopausal women. *Psychoneuroendocrinology* 2014; 46:52-63.
- [98] Kranz GS, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R, Kasper S. Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-¹¹C]WAY-100635. *Psychoneuroendocrinology* 2014; 45:1-10.
- [99] Neudorfer C, Shanab K, Jurik A, Schreiber V, Neudorfer C, Vranka C, Schirmer E, Holzer W, Ecker G, Mitterhauser M, Wadsak W, Spreitzer H. Development of potential selective and reversible pyrazoline based MAO-B inhibitors as MAO-B PET tracer precursors and reference substances for the early detection of Alzheimer's disease. *Bioorganic & Medicinal Chemistry Letters* 2014; 24: 4490-4495.
- [100] Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz GS, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R. The norepinephrine transporter in attention deficit and hyperactivity disorder investigated with (S,S)-[¹⁸F]FMENR-D2. *JAMA Psychiatry* 2014; Oct 22. [Epub ahead of print].
- [101] Bauer M, Karch R, Zeitlinger M, Liu J, Koepp MJ, Asselin MC, Sisodiya SM, Hainfellner JA, Wadsak W, Mitterhauser M, Müller M, Pataria E, Langer O. In vivo P-glycoprotein function before and after epilepsy surgery. *Neurology* 2014; 83: 1326-1331.
- [102] Baldinger P, Höflich A, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Hacker M, Lanzenberger R, Kasper S. Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. *International Journal of Neuropsychopharmacology* 2014; in press.
- [103] Kraus C, Baldinger P, Rami-Mark C, Gryglewski G, Kranz GS, Haeusler D, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R. Exploration the impact of BDNF Val66Met genotype on serotonin transporter and serotonin-1A receptor binding. *PLoS one* 2014; 9: e106810.
- [104] Sesti A, Mayerhoefer M, Weber M, Anner W, Wadsak W, Dudczak R, Haug A, Karanikas G. Relevance of Calcitonin Cut-off in the Follow-Up of Medullary Thyroid Carcinoma for Conventional Imaging and 18-Fluorine-Fluorodihydroxyphenylalanine PET. *Anticancer Research* 2014; 34:11.
- [105] Kranz G, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R. High-dose testosterone treatment increases serotonin transporter binding in transgender people. *Biological Psychiatry* 2014; in press.

Book chapters

- [106] Philippe C, Mitterhauser M, Wadsak W. Synthesis of 2-(4-N-[¹¹C]methylaminophenyl)-6-hydroxybenzothiazole ([¹¹C]6-OH-BTA-1; [¹¹C]PIB). Chapter 18. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography* Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.
- [107] Haeusler D, Mitterhauser M, Wadsak W. Synthesis of 3-amino-4-[2-(N-methyl-N-[¹¹C]methyl-amino-methyl)phenylsulfanyl]-benzonitrile ([¹¹C]DASB). Chapter 28. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography*; Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.
- [108] Eidherr H, Girschele F, Mitterhauser M, Wadsak W. Synthesis of [⁶⁸Ga]gallium DOTA-(Tyr³)-octreotide acetate (⁶⁸Ga-DOTATOC). Chapter 32. In: *Radiochemical Syntheses, Volume 1, Radiopharmaceuticals for Positron Emission Tomography*; Scott PJH, Hockley BG (eds.); 1st edition, John Wiley & Sons; 2012.